Um, you know, that seems to be expanding rapidly, these different contributors, and what does that mean for drug developers?

So it certainly means-- So heterogeneity, as you said, Selina, is something that is used differently in different ways but always seems to land on ALS when w-people describe it, and that, uh, in some ways, I think they're, they're, um, bringing different things together.

Uh, and it may not be as heterogeneous as, as, uh, people currently believe, but it is very true that science is leading us, uh, to look at a number of different pathways, and just when we feel that we've clearly answered one pathway as not important, another one shows up.

So there's very much a, um, whack-a-mole approach to, to, um, mechanist-mechanisms in ALS.

You d- um, and with, um, historically, the difficulty getting, uh, finding effective drugs, it's made that actually more intense.

So if you look at the current pathways that we're actively exploring already in clinical, you have, uh, things related to TDP-forty-three, um, including UNTHIRTEEN and Stasmin.

We have, um, we have, um, inflammation that is currently being tackled.

Hmm.